Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer

Yuji Miyamoto, Eiji Oki, Yasunori Emi, Shoji Tokunaga, Mototsugu Shimokawa, Yutaka Ogata, Yoshito Akagi, Yasuo Sakamoto, Takaho Tanaka, Hiroshi Saeki, Yoshihiko Maehara, Hideo Baba

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.

Original languageEnglish
Pages (from-to)491-499
Number of pages9
JournalAnticancer research
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this